THE Geneva-based Medicines Patent Pool (MPP) on Thursday announced
new generic manufacturing licences for four antiretrovirals and a
hepatitis C drug.
"These new sublicences will secure greater volumes of low-cost medicines for people living with HIV/AIDS and hepatitis C in low-and middle-income countries‚" said Greg Perry‚ MPP’s executive director. "We look forward to working with the companies to speed delivery of these treatments to those most in need of better medical options."
The MPP is a UN-backed public health organisation. MPP’s long-time generic partner, Aurobindo, signed two new sublicences. The first allows the company to produce lopinavir and ritonavir for Africa.
The organisation also signed licences with Aurobindo‚ Desano‚ Emcure‚ Hetero Labs‚ Laurus Labs‚ Lupin and new partner Zydus Cadila, for a total of nine new sublicensing agreements to produce generic versions of key World Health Organisation-priority HIV and hepatitis C treatments.
Desano‚ a Chinese manufacturer based in Shanghai‚ and Emcure signed licences for lopinavir and ritonavir. "Desano welcomes the opportunity of supporting increased volumes of this crucial treatment for people living with HIV/Aids in Africa‚ and specifically for SA‚ which has the largest HIV/AIDS treatment programme in the world‚" Tun Guo‚ director and company secretary‚ said.
The MPP’s 13 generic manufacturing partners are currently working on more than 60 projects to develop crucial treatments for both children and adults in developing world settings.
"These new sublicences will secure greater volumes of low-cost medicines for people living with HIV/AIDS and hepatitis C in low-and middle-income countries‚" said Greg Perry‚ MPP’s executive director. "We look forward to working with the companies to speed delivery of these treatments to those most in need of better medical options."
The MPP is a UN-backed public health organisation. MPP’s long-time generic partner, Aurobindo, signed two new sublicences. The first allows the company to produce lopinavir and ritonavir for Africa.
The organisation also signed licences with Aurobindo‚ Desano‚ Emcure‚ Hetero Labs‚ Laurus Labs‚ Lupin and new partner Zydus Cadila, for a total of nine new sublicensing agreements to produce generic versions of key World Health Organisation-priority HIV and hepatitis C treatments.
Desano‚ a Chinese manufacturer based in Shanghai‚ and Emcure signed licences for lopinavir and ritonavir. "Desano welcomes the opportunity of supporting increased volumes of this crucial treatment for people living with HIV/Aids in Africa‚ and specifically for SA‚ which has the largest HIV/AIDS treatment programme in the world‚" Tun Guo‚ director and company secretary‚ said.
The MPP’s 13 generic manufacturing partners are currently working on more than 60 projects to develop crucial treatments for both children and adults in developing world settings.
No comments:
Post a Comment